DiarrheaPhase 3YakultNCT00534170
Randomized Controlled Field Trial of a Probiotics to Assess Its Role in Preventig Diarrhoea
A Phase 3 study testing Probiotic (Yakult) in people with Diarrhea, run by Indian Council of Medical Research at 1 site in India.
Trial summary
A therapeutic as well as preventive role of probiotics has been suggested from results of different studies using different probiotics that have been tested, usually lactic acid producing bacteria such as lactobacillus, bifidobacterium and streptococcus species. Read more about this study
- Who is it for?
- Ages 12 to 59 monthsHealthy volunteers can take part
- Conditions the study is for
- Diarrhea
- What is being tested?
- Probiotic (Yakult)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 4,000 participants
- Where
- 1 siteIndia
- Study dates
- Jun 2007to Jan 2008
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 59 months
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Children of either sex aged 1-5 years will be eligible for screening and parents will give and a written, informed consent form will be required from either of the parents/ guardians of each participating child.
- Participating children should be free from any chronic illness and also any recent illness that may compromise the immune system. In general they will have good health without known underlying illness
Who cannot join
- Children below -2SD of the National Center for Health Statistics (NCHS) reference median in the nutritional parameters will not be enrolled.
- Children with history of diarrhoea in the preceding 2 weeks will not be eligible.
Trial locations and contacts
1 site in 1 country.
India1 site
National Institute of Cholera and Enteric Disease
Kolkata, West Bengal, 7000010
About this study
Official title: Randomized Controlled Field Trial of a Probiotics to Assess Its Role in The Prevention of Acute Diarrhoeal Diseases in Children
A therapeutic as well as preventive role of probiotics has been suggested from results of different studies using different probiotics that have been tested, usually lactic acid producing bacteria such as lactobacillus, bifidobacterium and streptococcus species. The supplementation of probiotics to infants may also have a prophylactic effect against acute diarrhoeal diseases.
In the present proposal, we plan to examine if daily intake of a probiotic beverage, which includes 15 billion probiotic Lactobacilli, has a beneficial role in protecting children from infectious diarrhea in Kolkata.
Read more
OBJECTIVES
Primary objectives:
- To assess the impact of probiotics in the prevention of acute diarrhoeal diseases in children
- To assess the impact of probiotics on nutrition and growth of the children
Secondary Objectives:
- Reduction in duration, frequency of diarrhoea
- Identification of pathogens causing diarrhoea
- Examination of faecal microflora
STUDY DESIGN
It will be a double blind randomized controlled field trial involving 4000 children aged between 1 and 5 years in an urban slum of Kolkata, India. The 4000 children will be identified through demographic survey. The study will be double blinded where the study arm will receive Probiotic drink, which includes 15 billion probiotic Lactobacilli, one bottle (65ml) daily (under supervision of a Health Worker) for 12 weeks and the control arm will receive a similar drink without the lactobacilli (Nutrient drink) daily for 12 weeks. Randomization will be done in a ratio of 1:1, i.e., the study arm and control arm will include 2000 children each. All the children under the study will be visited daily by a health worker who will supervise intake of Probiotic drink or Nutrient drink by the children. All the children will be followed up daily for 24weeks for identification of acute diarrhoea cases.
Read the detailed description
A therapeutic as well as preventive role of probiotics has been suggested from results of different studies using different probiotics that have been tested, usually lactic acid producing bacteria such as lactobacillus, bifidobacterium and streptococcus species. The supplementation of probiotics to infants may also have a prophylactic effect against acute diarrhoeal diseases.
In the present proposal, we plan to examine if daily intake of a probiotic beverage, which includes 15 billion probiotic Lactobacilli, has a beneficial role in protecting children from infectious diarrhea in Kolkata.
OBJECTIVES
Primary objectives:
- To assess the impact of probiotics in the prevention of acute diarrhoeal diseases in children
- To assess the impact of probiotics on nutrition and growth of the children
Secondary Objectives:
- Reduction in duration, frequency of diarrhoea
- Identification of pathogens causing diarrhoea
- Examination of faecal microflora
STUDY DESIGN
It will be a double blind randomized controlled field trial involving 4000 children aged between 1 and 5 years in an urban slum of Kolkata, India. The 4000 children will be identified through demographic survey. The study will be double blinded where the study arm will receive Probiotic drink, which includes 15 billion probiotic Lactobacilli, one bottle (65ml) daily (under supervision of a Health Worker) for 12 weeks and the control arm will receive a similar drink without the lactobacilli (Nutrient drink) daily for 12 weeks. Randomization will be done in a ratio of 1:1, i.e., the study arm and control arm will include 2000 children each. All the children under the study will be visited daily by a health worker who will supervise intake of Probiotic drink or Nutrient drink by the children. All the children will be followed up daily for 24weeks for identification of acute diarrhoea cases.
METHODOLOGY
Slum areas in Kolkata Municipal Corporation with approximately 60,000 populations (approximate 15,000 families) will be selected from ward 66 to reach a sample size of minimum 4,000 children (1-5 year age).
Baseline anthropometric measurements will be taken. The diarrhoeal surveillance will be through regular household visit by CHW and stool container will be kept at each child's house to collect stool sample if diarrhoea occurs.
INCLUSION/ EXCLUSION CRITERION FOR RECRUITMENT OF PARTICIPANTS Children of either sex aged 1-5 years will be eligible for screening and parents will give and a written, informed consent form (Appendix 7) will be required from either of the parents/ guardians of each participating child. Participating children should be free from any chronic illness and also any recent illness that may compromise the immune system. In general they will have good health without known underlying illness.
Children with history of diarrhoea in the preceding 2 weeks will not be eligible.
ADMINISTRATION OF STUDY AGENTS
There will be a setup of 5 health outposts and 20 clusters (each cluster with 40 children) will be approximately of 800 children will be assigned for each health outpost. There will be 20 Community Health Workers (CHW), allocated in each health outpost will be responsible for administer of one agent code for 40 children.
SAFETY EVALUATION
Clinical monitor will evaluate adverse events due to intake of the drink.
DATA MANAGEMENT PROCEDURES
Data obtained from demographic survey (Appendix 4), daily reports and other proforma will be entered in a PC using suitable software. Data will be scrutinized for accuracy and consistency before it is entered into the PC. Data will be entered into computers in a dedicated area located at NICED, using data entry programs specially created for the project by programmer.
STATISTICAL CONSIDERATIONS
Endpoints
Efficacy will be assessed by comparing the following between the probiotic and nutrient groups:
- Average duration of diarrhoea ii) Severity of the disease iii) Incidence of diarrhoeal disease iv) Nutritional gain v) Analysis of fecal microflora
ETHICAL ASSURANCE FOR PROTECTION OF HUMAN RIGHTS
Written informed consent will be obtained from the parent/guardian of each participating child for the Probiotic and Nutrition studies and for the safety and for permission to collect feces. The probiotic or nutritional drink is safe and has been administered to infant children, adults and the elderly.
Storage conditions
The probiotic and nutrient will be stored at 4 to 10C. Bottles taken to the field will be carried in carrying bags. Each box will have a single ice pack, and care will be taken not to freeze the contents of the bottle.
MONITORING, AUDITING, INSPECTION
Responsibilities of the investigator(s)
The principal and co-investigators at NICED will be responsible for overall supervision and management of the project. Field investigators and other co-investigators will support the PI. The PI and co-investigators will supervise all activities at health facilities and in the sites (demographic surveillance, data collection, and samples collection and transportation). They will also visit the study sites regularly.
ETHICAL AND REGULATORY STANDARDS
Ethical principle
The justification for using a nutrient in this study is that: 1) no probiotic is currently recommended for use for prevention of diarrhoeal diseases in public health programs in India and 2) a valid assessment of probiotic efficacy in Kolkata, which is endemic for diarrhoea, can only be obtained with use of a nutrient. The nutrient will consist of nutrient without lactobacillus, which will help for nutritional growth of the children.
Potential benefits
During both phases of the project, the potential benefits to participants include proper treatment and referral when needed, as well as free and accurate diagnosis of the causative agent of diarrhoeal disease. During the trial phase, the probiotic recipients are expected to benefit from the protection offered by the probiotic against diarrhoea.
Potential risks
The potential risk to the participants will be minimal, since there is extensive documentation for the safety of the probiotic to be used.
Risk/benefit ratio
The direct benefit the participants may expect from participating in this study will be free laboratory examination and treatment for diarrhoea diseases.
The main benefit of obtaining data on the efficacy of the probiotic in Kolkata will be that these data will be crucial in guiding the decision of the Indian, and perhaps other developing country governments as to whether this probiotic will be alternative approach for growth of the children as well as prevention of diarrhoeal diseases. All recipients of the probiotic will potentially benefit from the probable protective effects against diarrhoea. The risks associated with the use of the probiotic or the nutrient and various other study procedures proposed to be used in this trial are expected to be minimal to nonexistent.
Laws and regulations
The study will be performed in accordance with the principles that govern biomedical research involving human subjects, specifically the ICMR Ethical Guidelines, the Declaration of Helsinki, and the International Conference on Harmonization's Good Clinical Practice Guidelines to provide assurance that the rights, integrity, and confidentiality of trial subjects are protected and that reported results are credible and accurate.
Informed consent
Individual informed consents from parents of eligible children between 1-5 years old will be obtained. Consent will be documented by signature or thumbprint of the parents/guardian on separate sheet. The privacy and confidentiality of all data and information collected from trial participants will be ensured both during and after the conduct of the trial. Individuals will not be identified in any reports and publications based on the trial data.
Institutional review committee
Before initiation of the study, the final protocol and the informed consent will require clearance Scientific Advisory Committee of NICED, Institutional Ethics Committee of NICED, Health Ministry Screening Committee of the Government of India.
ADMINISTRATIVE ASPECTS
Record retention
The principal investigator and NICED will keep all trial documents for at least 5 years after the completion or discontinuation of the study.
KEY PERSONNEL Name Professional Discipline/ Specialty Role in the Project
- 1. Dipika Sur Epidemiology PI in India
- 2. S.K. Bhattacharya Cholera and enteric disease Co-PI in India
- 4. Byomkesh Manna Epidemiology Co-I in India
- 5. S.K. Niyogi Microbiology Co-I in India
- 6 Anup Palit Microbiology Co-I in India
- 7. S.P. Mukhopadhyay Public health Controller
- 8. Ashok Chowdhury Clinician Clinical Monitor
- Conditions
- Diarrhea
- Being tested
- Probiotic (Yakult)
- Keywords
- Probiotic, Prevention of diarrhoea, Nutritional status
- Medical subject headings
- Diarrhea
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Probiotic (Yakult)Dietary supplement
Also called Yakult
It is a dietary supplement ,65 ml containing 15 billion lactobacillus
| Study group | Role | What they receive |
|---|---|---|
| A,F,T,K | Experimental | Two arms are for intervention and two are for control or placebo Receives: Dietary Supplement: Probiotic (Yakult) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Diarrhoeal episodes in children
Measured: 10 months
Secondary outcomes (1)
nutritional status in children
Measured: 10 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2007 (estimated)
- Study startJun 2007
- Study completionJan 2008 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for DiarrheaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 4,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- Indian Council of Medical Research
- Sponsor type
- Other government
- Collaborators
- Yakult Honsha Co., LTD
- Investigators
- Dr.Dipika Sur, MD, Principal investigator, National Institute of Cholera and Enteric Diseases, India
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00534170
- Sponsor's protocol ID
- YH-001 NICED 010
- Acronym
- Yakult
- Status last verified
- Jun 2007
- First submitted
- 21 Sep 2007
- Last updated
- 24 Sep 2007
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Sur D, Manna B, Niyogi SK, Ramamurthy T, Palit A, Nomoto K, Takahashi T, Shima T, Tsuji H, Kurakawa T, Takeda Y, Nair GB, Bhattacharya SK. Role of probiotic in preventing acute diarrhoea in children: a community-based, randomized, double-blind placebo-controlled field trial in an urban slum. Epidemiol Infect. 2011 Jun;139(6):919-26. doi: 10.1017/S0950268810001780. Epub 2010 Jul 30.
PubMed 20670468
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2007. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Controlled Field Trial of a Probiotics to Assess Its Role in The Prevention of Acute Diarrhoeal Diseases in Children
- ClinicalTrials.gov ID
- NCT00534170
- Acronym / sponsor ID
- Yakult / YH-001 NICED 010
- Conditions
- Diarrhea
- Keywords
- Probiotic, Prevention of diarrhoea, Nutritional status
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 4,000 participants (actual)
- Lead sponsor
- Indian Council of Medical ResearchOther government
- Collaborators
- Yakult Honsha Co., LTD
- Study start
- Jun 2007
- Study completion
- Jan 2008 (estimated)
- First posted
- 24 Sep 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A therapeutic as well as preventive role of probiotics has been suggested from results of different studies using different probiotics that have been tested, usually lactic acid producing bacteria such as lactobacillus, bifidobacterium and streptococcus species. The supplementation of probiotics to infants may also have a prophylactic effect against acute diarrhoeal diseases.
In the present proposal, we plan to examine if daily intake of a probiotic beverage, which includes 15 billion probiotic Lactobacilli, has a beneficial role in protecting children from infectious diarrhea in Kolkata.
OBJECTIVES
Primary objectives:
- To assess the impact of probiotics in the prevention of acute diarrhoeal diseases in children
- To assess the impact of probiotics on nutrition and growth of the children
Secondary Objectives:
- Reduction in duration, frequency of diarrhoea
- Identification of pathogens causing diarrhoea
- Examination of faecal microflora
STUDY DESIGN
It will be a double blind randomized controlled field trial involving 4000 children aged between 1 and 5 years in an urban slum of Kolkata, India. The 4000 children will be identified through demographic survey. The study will be double blinded where the study arm will receive Probiotic drink, which includes 15 billion probiotic Lactobacilli, one bottle (65ml) daily (under supervision of a Health Worker) for 12 weeks and the control arm will receive a similar drink without the lactobacilli (Nutrient drink) daily for 12 weeks. Randomization will be done in a ratio of 1:1, i.e., the study arm and control arm will include 2000 children each. All the children under the study will be visited daily by a health worker who will supervise intake of Probiotic drink or Nutrient drink by the children. All the children will be followed up daily for 24weeks for identification of acute diarrhoea cases.
Detailed description
A therapeutic as well as preventive role of probiotics has been suggested from results of different studies using different probiotics that have been tested, usually lactic acid producing bacteria such as lactobacillus, bifidobacterium and streptococcus species. The supplementation of probiotics to infants may also have a prophylactic effect against acute diarrhoeal diseases.
In the present proposal, we plan to examine if daily intake of a probiotic beverage, which includes 15 billion probiotic Lactobacilli, has a beneficial role in protecting children from infectious diarrhea in Kolkata.
OBJECTIVES
Primary objectives:
- To assess the impact of probiotics in the prevention of acute diarrhoeal diseases in children
- To assess the impact of probiotics on nutrition and growth of the children
Secondary Objectives:
- Reduction in duration, frequency of diarrhoea
- Identification of pathogens causing diarrhoea
- Examination of faecal microflora
STUDY DESIGN
It will be a double blind randomized controlled field trial involving 4000 children aged between 1 and 5 years in an urban slum of Kolkata, India. The 4000 children will be identified through demographic survey. The study will be double blinded where the study arm will receive Probiotic drink, which includes 15 billion probiotic Lactobacilli, one bottle (65ml) daily (under supervision of a Health Worker) for 12 weeks and the control arm will receive a similar drink without the lactobacilli (Nutrient drink) daily for 12 weeks. Randomization will be done in a ratio of 1:1, i.e., the study arm and control arm will include 2000 children each. All the children under the study will be visited daily by a health worker who will supervise intake of Probiotic drink or Nutrient drink by the children. All the children will be followed up daily for 24weeks for identification of acute diarrhoea cases.
METHODOLOGY
Slum areas in Kolkata Municipal Corporation with approximately 60,000 populations (approximate 15,000 families) will be selected from ward 66 to reach a sample size of minimum 4,000 children (1-5 year age).
Baseline anthropometric measurements will be taken. The diarrhoeal surveillance will be through regular household visit by CHW and stool container will be kept at each child's house to collect stool sample if diarrhoea occurs.
INCLUSION/ EXCLUSION CRITERION FOR RECRUITMENT OF PARTICIPANTS Children of either sex aged 1-5 years will be eligible for screening and parents will give and a written, informed consent form (Appendix 7) will be required from either of the parents/ guardians of each participating child. Participating children should be free from any chronic illness and also any recent illness that may compromise the immune system. In general they will have good health without known underlying illness.
Children with history of diarrhoea in the preceding 2 weeks will not be eligible.
ADMINISTRATION OF STUDY AGENTS
There will be a setup of 5 health outposts and 20 clusters (each cluster with 40 children) will be approximately of 800 children will be assigned for each health outpost. There will be 20 Community Health Workers (CHW), allocated in each health outpost will be responsible for administer of one agent code for 40 children.
SAFETY EVALUATION
Clinical monitor will evaluate adverse events due to intake of the drink.
DATA MANAGEMENT PROCEDURES
Data obtained from demographic survey (Appendix 4), daily reports and other proforma will be entered in a PC using suitable software. Data will be scrutinized for accuracy and consistency before it is entered into the PC. Data will be entered into computers in a dedicated area located at NICED, using data entry programs specially created for the project by programmer.
STATISTICAL CONSIDERATIONS
Endpoints
Efficacy will be assessed by comparing the following between the probiotic and nutrient groups:
- Average duration of diarrhoea ii) Severity of the disease iii) Incidence of diarrhoeal disease iv) Nutritional gain v) Analysis of fecal microflora
ETHICAL ASSURANCE FOR PROTECTION OF HUMAN RIGHTS
Written informed consent will be obtained from the parent/guardian of each participating child for the Probiotic and Nutrition studies and for the safety and for permission to collect feces. The probiotic or nutritional drink is safe and has been administered to infant children, adults and the elderly.
Storage conditions
The probiotic and nutrient will be stored at 4 to 10C. Bottles taken to the field will be carried in carrying bags. Each box will have a single ice pack, and care will be taken not to freeze the contents of the bottle.
MONITORING, AUDITING, INSPECTION
Responsibilities of the investigator(s)
The principal and co-investigators at NICED will be responsible for overall supervision and management of the project. Field investigators and other co-investigators will support the PI. The PI and co-investigators will supervise all activities at health facilities and in the sites (demographic surveillance, data collection, and samples collection and transportation). They will also visit the study sites regularly.
ETHICAL AND REGULATORY STANDARDS
Ethical principle
The justification for using a nutrient in this study is that: 1) no probiotic is currently recommended for use for prevention of diarrhoeal diseases in public health programs in India and 2) a valid assessment of probiotic efficacy in Kolkata, which is endemic for diarrhoea, can only be obtained with use of a nutrient. The nutrient will consist of nutrient without lactobacillus, which will help for nutritional growth of the children.
Potential benefits
During both phases of the project, the potential benefits to participants include proper treatment and referral when needed, as well as free and accurate diagnosis of the causative agent of diarrhoeal disease. During the trial phase, the probiotic recipients are expected to benefit from the protection offered by the probiotic against diarrhoea.
Potential risks
The potential risk to the participants will be minimal, since there is extensive documentation for the safety of the probiotic to be used.
Risk/benefit ratio
The direct benefit the participants may expect from participating in this study will be free laboratory examination and treatment for diarrhoea diseases.
The main benefit of obtaining data on the efficacy of the probiotic in Kolkata will be that these data will be crucial in guiding the decision of the Indian, and perhaps other developing country governments as to whether this probiotic will be alternative approach for growth of the children as well as prevention of diarrhoeal diseases. All recipients of the probiotic will potentially benefit from the probable protective effects against diarrhoea. The risks associated with the use of the probiotic or the nutrient and various other study procedures proposed to be used in this trial are expected to be minimal to nonexistent.
Laws and regulations
The study will be performed in accordance with the principles that govern biomedical research involving human subjects, specifically the ICMR Ethical Guidelines, the Declaration of Helsinki, and the International Conference on Harmonization's Good Clinical Practice Guidelines to provide assurance that the rights, integrity, and confidentiality of trial subjects are protected and that reported results are credible and accurate.
Informed consent
Individual informed consents from parents of eligible children between 1-5 years old will be obtained. Consent will be documented by signature or thumbprint of the parents/guardian on separate sheet. The privacy and confidentiality of all data and information collected from trial participants will be ensured both during and after the conduct of the trial. Individuals will not be identified in any reports and publications based on the trial data.
Institutional review committee
Before initiation of the study, the final protocol and the informed consent will require clearance Scientific Advisory Committee of NICED, Institutional Ethics Committee of NICED, Health Ministry Screening Committee of the Government of India.
ADMINISTRATIVE ASPECTS
Record retention
The principal investigator and NICED will keep all trial documents for at least 5 years after the completion or discontinuation of the study.
KEY PERSONNEL Name Professional Discipline/ Specialty Role in the Project
- 1. Dipika Sur Epidemiology PI in India
- 2. S.K. Bhattacharya Cholera and enteric disease Co-PI in India
- 4. Byomkesh Manna Epidemiology Co-I in India
- 5. S.K. Niyogi Microbiology Co-I in India
- 6 Anup Palit Microbiology Co-I in India
- 7. S.P. Mukhopadhyay Public health Controller
- 8. Ashok Chowdhury Clinician Clinical Monitor
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| A,F,T,K | Experimental | Dietary Supplement: Probiotic (Yakult)Two arms are for intervention and two are for control or placebo |
Who may qualify
- Ages
- 12 to 59 months
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (2 listed)
- Children of either sex aged 1-5 years will be eligible for screening and parents will give and a written, informed consent form will be required from either of the parents/ guardians of each participating child.
- Participating children should be free from any chronic illness and also any recent illness that may compromise the immune system. In general they will have good health without known underlying illness
Key exclusion criteria (2 listed)
- Children below -2SD of the National Center for Health Statistics (NCHS) reference median in the nutritional parameters will not be enrolled.
- Children with history of diarrhoea in the preceding 2 weeks will not be eligible.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Probiotic (Yakult)Also: YakultIt is a dietary supplement ,65 ml containing 15 billion lactobacillus | Dietary supplement | A,F,T,K |
Primary outcome
Diarrhoeal episodes in children
Time frame: 10 months
1 secondary outcome
nutritional status in children
Time frame: 10 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2007.
- Derived from this study: PubMed 20670468Sur D, Manna B, Niyogi SK, Ramamurthy T, Palit A, Nomoto K, Takahashi T, Shima T, Tsuji H, Kurakawa T, Takeda Y, Nair GB, Bhattacharya SK. Role of probiotic in preventing acute diarrhoea in children: a community-based, randomized, double-blind placebo-controlled field trial in an urban slum. Epidemiol Infect. 2011 Jun;139(6):919-26. doi: 10.1017/S0950268810001780. Epub 2010 Jul 30.
Related trials for Diarrhea
Not yet recruiting
Comparison of Two Probiotics for Reducing Diarrhea Frequency in Children Aged 6-24 Months
Acute Watery Diarrhea, Acute Watery Diarrhoea
RecruitingPhase 2
Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children
Diarrhoea
RecruitingPhase 2
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
Irritable Bowel Syndrome, Diarrhea
Recruiting
Lactic Acid Bacteria in Functional Diarrheal Disorders
IBS-D (Diarrhea-predominant), IBS (Irritable Bowel Syndrome)
RecruitingPhase 2
Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)
Immune-related Adverse Event, Diarrhea
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dr.Dipika Sur, MD principal investigator
National Institute of Cholera and Enteric Diseases, India
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Probiotic (Yakult) in people with Diarrhea, run by Indian Council of Medical Research at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 24 Sep 2007. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Diarrhoeal episodes in children (time frame: 10 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00534170, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2007.